Pfizer raised profit estimates for 2025 thanks to cost cuts, despite falling COVID product revenue and patent expirations.
Sanziana Georgescu
Economy
sursa foto: shutterstock.com
Always see our news on Google
Pfizer has announced a revised profit estimate for 2025, underpinned by a cost-cutting program, amid falling COVID product revenues and patent expirations. Shares rose 3.7% after the company reported a better-than-expected quarterly profit. However, Pfizer remains cautious, maintaining annual sales forecasts of between $61 billion and $64 billion, due to pandemic uncertainties and political pressure to cut drug prices.
Sources
Pfizer își majorează estimarea de profit pentru 2025, pe fondul reducerilor masive de costuri și al presiunilor politice din partea lui Trump
Pfizer își ridică prognoza de profit pentru 2025, mizând pe reduceri agresive de costuri și negocieri
Pfizer îşi majorează estimarea de profit pentru 2025, pe fondul reducerilor masive de costuri şi al presiunilor politice din partea lui Trump
Pfizer îşi majorează estimarea de profit pentru 2025, pe fondul reducerilor masive de costuri şi al presiunilor politice din partea lui Trump
Latest News
14:10
The Houthi rebels say they will no longer attack American ships, but warn that Saudi Arabia remains a target
14:01
Google fined €403 million for violating rules on geolocation data
13:34
Nicusor Dan met with Ronald S. Lauder in New York and reaffirmed Romania’s commitment to combating antisemitism
13:30
Grindeanu: PSD will not vote for the Bolojan 2.0 Government, referring to designated prime minister Siegfried Mureșan
13:28
Siegfried Mureșan: “We will not have a dialogue with AUR. The moment of truth is coming for the PSD. Let’s see whether the PSD really wants to support a pro-European government.”
See more news
NEWS ON THE SAME TOPICS
.webp)
Personalized news feed, AI-powered search, and notifications in a more interactive experience.
.webp)
